drugset / Trial / NCT06992687
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Phase 1/2
Enrolling by invitation
30 enrolled
Shanghai Huaota Biopharmaceutical Co., Ltd.
Huazhong University of Science and Technology · collabHunan Cancer Hospital · collabPeking University Cancer Hospital & Institute · collabShandong Cancer Hospital and Institute · collabThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collabThe Second Affiliated Hospital of Harbin Medical University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
Timeline
- Start
- 2024-09-01
- Primary completion
- 2025-09-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0052 | Other / unclassified | — | Intravenous |